dc.contributor.author |
Crabtree-Ramírez, B. |
|
dc.contributor.author |
Jenkins, C. |
|
dc.contributor.author |
Jayathilake, K. |
|
dc.contributor.author |
Carriquiry, G. |
|
dc.contributor.author |
Veloso, V. |
|
dc.contributor.author |
Padgett, D. |
|
dc.contributor.author |
Gotuzzo Herencia, José Eduardo |
|
dc.contributor.author |
Cortes, C. |
|
dc.contributor.author |
Mejía Cordero, Fernando Alonso |
|
dc.contributor.author |
McGowan, C.C. |
|
dc.contributor.author |
Duda, S. |
|
dc.contributor.author |
Shepherd, B.E. |
|
dc.contributor.author |
Sterling, T.R. |
|
dc.date.accessioned |
2019-12-06T20:57:49Z |
|
dc.date.available |
2019-12-06T20:57:49Z |
|
dc.date.issued |
2019 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/7436 |
|
dc.description.abstract |
BACKGROUND: Tuberculosis (TB) diagnosis in human immunodeficiency virus (HIV) positive persons is difficult, particularly in resource-limited settings. The relationship between TB culture status and mortality in HIV-positive persons treated for TB is unclear. METHODS : We evaluated HIV-positive adults treated for TB at or after their first HIV clinic visit in Argentina, Brazil, Chile, Honduras, Mexico or Peru from 2000 to 2015. Anti-tuberculosis treatment included 2 months of isoniazid, rifampicin (RMP)/rifabutin (RBT), pyrazinamide 6 ethambutol, followed by continuation phase treatment with isoniazid + RMP/RBT. RESULTS : Of 759 TB-HIV patients, 238 (31%) were culture-negative, 228 (30%) had unknown culture status or did not undergo culture and 293 (39%) were culturepositive. The median CD4 at TB diagnosis was 96 (interquartile range 40-228); 636 (84%) received concurrent antiretroviral therapy (ART) and antituberculosis treatment. There were 123 (16%) deaths: 90/466 (19%) with TB culture-negative, unknown or not performed vs. 33/293 (11%) who were TB culturepositive (P=0.005). In Kaplan-Meier analysis, mortality in TB patients without culture-confirmed disease was higher (P=0.002). In a Cox model adjusted for age, sex, CD4, ART timing, disease site and stratified by study site, mortality in persons without culture-confirmed TB was not significantly increased compared to those with culture-positive TB (hazard ratio 1.39, 95%CI 0.89- 2.16, P = 0.15). CONCLUSION: Most HIV-positive patients treated for TB did not have culture-confirmed TB, and mortality tended to be higher in patients without culture-confirmed disease, although the association was not statistically different after adjusting for other variables. Accurate TB diagnosis in HIV-positive persons is crucial. |
en_US |
dc.language.iso |
eng |
|
dc.publisher |
International Union Against Tuberculosis and Lung Disease |
|
dc.relation.ispartofseries |
International Journal of Tuberculosis and Lung Disease |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
adult |
en_US |
dc.subject |
age distribution |
en_US |
dc.subject |
Anti-tuberculosis treatment |
en_US |
dc.subject |
Argentina |
en_US |
dc.subject |
Article |
en_US |
dc.subject |
bacterial growth |
en_US |
dc.subject |
bacterium culture |
en_US |
dc.subject |
CD4 lymphocyte count |
en_US |
dc.subject |
Chile |
en_US |
dc.subject |
cohort analysis |
en_US |
dc.subject |
controlled study |
en_US |
dc.subject |
Culture-negative tuberculosis |
en_US |
dc.subject |
disease association |
en_US |
dc.subject |
ethambutol |
en_US |
dc.subject |
female |
en_US |
dc.subject |
genetic heterogeneity |
en_US |
dc.subject |
Honduras |
en_US |
dc.subject |
human |
en_US |
dc.subject |
Human immunodeficiency virus and TB |
en_US |
dc.subject |
Human immunodeficiency virus infection |
en_US |
dc.subject |
isoniazid |
en_US |
dc.subject |
Latin America |
en_US |
dc.subject |
log rank test |
en_US |
dc.subject |
major clinical study |
en_US |
dc.subject |
male |
en_US |
dc.subject |
Mexico |
en_US |
dc.subject |
mortality |
en_US |
dc.subject |
Peru |
en_US |
dc.subject |
priority journal |
en_US |
dc.subject |
probability |
en_US |
dc.subject |
pyrazinamide |
en_US |
dc.subject |
rifabutin |
en_US |
dc.subject |
rifampicin |
en_US |
dc.subject |
risk assessment |
en_US |
dc.subject |
tuberculosis |
en_US |
dc.subject |
World Health Organization |
en_US |
dc.title |
HIV-related tuberculosis: Mortality risk in persons without vs With culture-confirmed disease |
en_US |
dc.type |
info:eu-repo/semantics/article |
|
dc.identifier.doi |
https://doi.org/10.5588/ijtld.18.0111 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.03.08 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.02.07 |
|
dc.relation.issn |
1815-7920 |
|